InnoSkel appoints Dr Sophie Amsellem-Bosq as Technical Director

InnoSkel Appointed Dr Sophie Amsellem-Bosq as a chef Technical Officer

Pleasant, Francid, 14 December 2021 InnoSkel (the “Company”), a pioneering biotechnology platform developing transformative therapies for the unmet needs of people with rare bone diseases, today announces the appointment of Sophie Amsellem-Bosq, PharmD, PhD as Chief Technical Officer (CTO).

In her role as CTO, Sophie is responsible for overseeing the definition and deployment of all strategic CMC development and manufacturing activities within the company’s integrated platform, as Innoskel continues to grow its asset base. principal to the clinic and expand its pipeline to broader indications.

Sophie has over 20 years of experience in cell and gene therapy across the entire value chain, from discovery to clinical development and manufacturing, all the way to the bedside. She joins InnoSkel after advising and sharing her expertise with cell and gene therapy biotechnology companies and venture capital funds. Previously, Sophie served as Global CAR-T Program Director at international pharmaceutical company Servier, where she led the company’s CAR-T allogeneic pipeline development strategy and cross-functional coordination of related activities. She was responsible for the cell and gene therapy manufacturing business unit at Yposkesi (formerly Généthon Bioprod), a leading CDMO for the manufacture of viral gene therapy vectors, where she implemented the development from scratch. and the manufacture of genetically modified cellular pharmaceuticals. Sophie has held several versatile positions in various leading institutions such as the Gustave Roussy Cancer Center, Ambroise Paré Hospital and INSERM. She holds a PharmD from the University of Paris XI, Châtenay-Malabry and a PhD in blood cell biology from the University of Paris VII, Paris.

Elvire Gouze, PhD, Founder and CEO of InnoSkel, commented : Sophie’s passion for, and extensive experience in, the field of gene and cell therapy covers the entire value chain from bench to bedside and be invaluable to InnoSkel to advance our main breakthrough uncomfortable therapy toward the clinical. Its leadership in construction unprecedenteded technical development and operations capabilities will be critical to accelerating our progress and advancing our pipeline. There is an urgent need for viable treatment options to people patients with rare bone diseases and the InnoSkel team is uniquely placed to develop therapies for dramatically improve the lives of those with these troubles.

Sophie Amsellem-Bosq, PharmD, PhD, Chief Technology Officer at InnoSkel, added: InnoSkel is a pioneer in the development of innovative therapies for rare bone diseases. As gene therapy has already offered remarkable promise and treatments for many unmet medical needs, can’t wait to start with such an exceptional team implement innovative and efficient manufacturing solutions that will overcome current challenges for individuals with rare bone diseases. I look forward to working with Elvire and the team as we continue to to construct to work already being carried out at the Company and to advance these potentially transformative therapies in the clinic.

On InnoSkel
InnoSkel is a pioneering biotechnology company developing transformative therapies for the unmet needs of people with rare bone disorders. Initially, the Company is developing gene therapy for a group of diseases known as collagen type II disorders, while also expanding the use of its technology to target and treat other rare bone diseases caused by the lack of or the mutation of a single gene. InnoSkel’s main active ingredient, INS-101, is a gene therapy for type II collagen disorders which has shown good efficacy in proof of concept studies. The company’s goal is to make a meaningful difference in the lives of underserved patient populations with debilitating bone disorders. InnoSkel is a spin-out from Inserm’s Institut de Biologie Valrose, the French National Institute for Health and Medical Research, and is based in Sophia Antipolis, Nice, France.

For more information, visit

For more information please contact:


Elvire Gouze, Founder and CEO

[email protected]

Strategic Communication Consilium

Mary-Jane Elliott / Melissa Gardiner / Allison Connolly

[email protected]

Phone: +44 (0) 20 3709 5700

Main logo

Source link

Comments are closed.